RESUMO
The present study evaluated the effects of protocatechuic acid (PCA) after cisplatin-induced ovarian toxicity in mice and if PTEN and FOXO3a proteins are involved in PCA action. The mice were divided into five experimental groups (five animals per group) and treated once a day for 3 days as follows: (1) the control group was pretreated with oral administration (o.p.) of saline solution, followed by an intraperitoneal (i.p.) injection of saline solution. The other groups were pretreated (o.p.) with (2) saline solution (cisplatin group), (3) N-acetylcysteine (150 mg/kg of body weight), or with (4) 20 or (5) 50 mg/kg body weight of PCA, followed by 5 mg/kg body weight (i.p.) of cisplatin. Next, the ovaries were destined to histological (morphology and activation), immunohistochemical (PCNA and cleaved caspase-3 expression), and fluorescence (reactive oxygen species [ROS], glutathione [GSH], and active mitochondria levels) analyses. Moreover, the immunoreactivity for p-PTEN and p-FOXO3a was evaluated to investigate a potential mechanism by which PCA could prevent the cisplatin-induced ovarian damage. Pretreatment with N-acetylcysteine or 20 mg/kg PCA before cisplatin preserved the percentage of normal follicles and cell proliferation as observed in the control, reduced apoptosis and ROS levels, and showed higher active mitochondria and GSH levels than the cisplatin treatment (P < 0.05). Moreover, pretreatment with 20 mg/kg PCA decreased cisplatin-induced p-PTEN and increased (P < 0.05) nuclear export of p-FOXO3a. In conclusion, PCA at 20 mg/kg reduced apoptosis, maintained cell proliferation and mitochondrial function, reduced ROS production, and increased GSH expression likely through the involvement of PTEN and FOXO3a proteins.
Assuntos
Proteína Forkhead Box O3/metabolismo , Hidroxibenzoatos/farmacologia , Doenças Ovarianas/prevenção & controle , Ovário/efeitos dos fármacos , PTEN Fosfo-Hidrolase/metabolismo , Substâncias Protetoras/farmacologia , Animais , Apoptose/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Cisplatino , Modelos Animais de Doenças , Feminino , Glutationa/metabolismo , Camundongos , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Mitocôndrias/patologia , Doenças Ovarianas/induzido quimicamente , Doenças Ovarianas/enzimologia , Doenças Ovarianas/patologia , Ovário/metabolismo , Ovário/patologia , Fosforilação , Espécies Reativas de Oxigênio/metabolismoRESUMO
Se analizaron 30 pacientes con SHO que ameritaron hospitalización. No hubodiferencia en cuando al tiempo de esterilidad y la aparición del síndrome. El uso de menotropinas causó el síndrome más frecuentemente. Hubo embarazo múltiple en 33 por ciento. La incidencia de aborto fue de 16 por ciento. Como se desconoce la etiología no existe un tratamiento adecuado, y las medidas son de sostén. La prevención es la mejor opción